MedTrace Logo

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

NCT02614482 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-07-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long term tolerability of Fesoterodine and its efficacy for overactive bladder syndrome in children.

Conditions

Interventions

DRUG

Fesoterodine

Administer medication to patients with overactive bladder

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Stéphane Bolduc

    lead OTHER

Principal Investigators

  • Stephane Bolduc, MD · CHU de Québec-Université Laval

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-06-30
Completion
2018-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614482 on ClinicalTrials.gov